Retinoic acid receptor α dominant negative form causes steatohepatitis and liver tumors in transgenic mice

Hepatology

Volumn 40, Issue 2, 2004, Pages 366-375

  Yanagitani, Atakshi ^a   Yamada, Sadako ^a   Yasui, Sakiko ^a   Shimomura, Takashi ^a   Murai, Rie ^a   Murawaki, Yoshiyuki ^a   Hashiguchi, Koichi ^a   Kanbe, Takamasa ^a   Saeki, Toshiya ^a   Ichiba, Miho ^a   Tanabe, Yoshitada ^a   Yoshida, Yoko ^a   Morino, Shin Ichi ^b   Kurimasa, Akihiro ^a   Usuda, Nobumitsu ^a   Yamazaki, Hidetoshi ^b   Kunisada, Takahiro ^c   Ito, Hisao ^d   Murawaki, Yoshikazu ^a   Shiota, Goshi ^a,e  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; 8 HYDROXYDEOXYGUANOSINE; ACYL COENZYME A OXIDASE; BETA CATENIN; BIFUNCTIONAL ENZYME; CYCLIN D1; CYTOCHROME P450; CYTOCHROME P450 4A10; CYTOCHROME P450 4A12; CYTOCHROME P450 4A14; HYDROGEN PEROXIDE; LIVER ENZYME; LONG ACYL COENZYME A DEHYDROGENASE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; T CELL FACTOR PROTEIN 4; UNCLASSIFIED DRUG; VERY LONG ACYL COENZYME A DEHYDROGENASE; WNT PROTEIN;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FATTY ACID METABOLISM; FATTY ACID OMEGA OXIDATION; FATTY ACID OXIDATION; HEPATITIS; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER NECROSIS; LIVER TUMOR; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; BETA CATENIN; CYTOSKELETAL PROTEINS; DEOXYGUANOSINE; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYMES; FATTY ACIDS; FATTY LIVER; GENES, DOMINANT; HYDROGEN PEROXIDE; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MITOCHONDRIA, LIVER; OXIDATION-REDUCTION; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TRANS-ACTIVATORS; TRETINOIN;

EID: 4043094220     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20335     Document Type: Article

References (41)

1. Chambon P. A decade of molecular biology of retinoic acid. FASEB J 1996;10:940-954.
2. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 1995;83:859-869.
3. Means AL, Gudas LJ. The roles of retinoids in vertebrate development. Annu Rev Biochem 1995;64:201-233.
4. Lotan R. Retinoids in cancer chemprevention. FASEB J 1996;10:1031-1039.
5. Ozeki A, Tsukamoto I. Retinoic acid repressed the expression of c-fos and c-jun induced apoptosis in regenerating rat liver after partial hepatectomy. Biochem Biophys Acta 1999;1450:308-319.
6. Seifert WF, Bosma A, Brouwer A, Henderiks HFJ, Roholl PJM, von Leeuwen REW, et al. Vitamin A deficiency potentiates carbon tetrachloride-induced liver fibrosis in rats. HEPATOLOGY 1994;19:193-201.
7. Li C, Wan Y-JY. Differentiation and antiproliferation effects of retinoic acid receptor β in hepatoma cells. Cancer Lett 1998;124:205-211.
8. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561-1567.
9. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan. Acta Hepatol Jpn 1995;36:208-218.
10. Li E, Sucov HM, Lee K-F, Evans RM, Jaenish R. Normal development and growth of mice carrying a targeted disruption of the alpha 1 retinoic acid receptor gene. Proc Natl Acad Sci U S A 1993;90:1590-1594.
11. Lohnes D, Kastner P, Dierich V, Mark M, LeMeur M, Chambon P. Function of retinoic acid receptor gamma in the mouse. Cell 1993;73:643-658.
12. Lufkin T, Lohnes D, Mark V, Dietrich A, Gorry P, Gaub MP, et al. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. Proc Natl Acad Sci U S A 1993;90:7225-7229.
13. Saitou M, Narumiya S, Kakizuka A. Alteration of a single amino acid residue in retinoic acid receptor causes dominant-negative phenotype. J Biol Chem 1994;269:19101-19107.
14. Saitou M, Sugai S, Tanaka T, Shimouchi K, Fuchs E, Narumiya S, et al. Inhibition of skin development by targeted expression of a dominant-negative phenotypes. Nature 1995;374:159-162.
15. Yamaguchi M, Nakamoto M, Honda H, Nakagawa T, Fujita H, Nakamura T, et al. Retardation of skeletal development and cervical abnormalities in transgenic mice expressing a dominant-negative retinoic acid receptor in chondrogenic cells. Proc Natl Acad Sci U S A 1998;95:7491-7496.
16. Tsutsumi A, Shiota G, Yamazaki H, Kunisada T, Terada T, Kawaski H. Accelerated growth of hepatocytes in association with up-regulation of cyclin E in transgenic mice expressing the dominant negative form of retinoic acid receptor. Biochem Biophys Res Commun 2000;278:229-235.
17. Frith CH, Ward JM. A morphological classification of proliferative and neoplastic hepatic lesions in mice. J Environ Pathol Toxicol 1980;3:329-351.
18. Kiso S, Kawata S, Tamura S, Inui Y, Yoshida Y, Sawai Y, et al. Liver regeneration in heparin-binding EGF-like growth factor transgenic mice after partial hepatectomy. Gastroenterology 2003;124:701-707.
19. Straub B, Muller M, Kraus H, Schrader M, Goessl C, Heicappell R, et al. Detection of prostate-specific antigen RNA before and after radical retro-public prostatectomy and transurethral resection of the prostate using "Light-cycler" based quantitative real-time polymerase chain reaction. Urology 2001;58:815-820.
20. Shindo Y, Osumi T, Hashimoto T. Effects of administration of di-(2-ethylhexyl) phthalate on rat liver mitochondria. Biochem Pharmacol 1978;27:2683-2688.
21. Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods 1980;38:161-170.
22. Pomerantz SC, McCloskey JA. Analysis of RNA hydrolyzates by liquid chromatography-mass spectrometry. Methods Enzymol 1990;193:796-824.
23. Rao MS, Reddy JK. Peroxisomal β-oxidation and steatohepatitis. Seminars in Liver Disease 2001;21:43-55.
24. Reddy JK, Mannaerts GP. Peroxisomal lipid metabolism. Annu Rev Nutr 1994;114:551-563.
25. Easwaran V, Pishvaian M, Byers SS. Cross-regulation of β-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 1999;9:1415-1418.
26. Gat U, DasGupta R, Degenstein L, Fuchs E. De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell 1998;95:605-614.
27. Nagao M, Parimoo B, Tanaka K. Developmental, nutritional, and hormonal regulation of tissue-specific expression of the genes encoding various acyl-CoA dehydrogenases and α-subunit of electron transfer flavoprotein in rat. J Biol Chem 1993;268:24114-24124.
28. Reddy JK, Goel SK, Nemali M R, Carrino JJ, Laffler TG, Reddy MK, et al. Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc Natl Acad Sci U S A 1986;83:1747-1751.
29. Nakae D, Kobayashi Y, Akai H, Andoh H, Satoh H, Ohashi K, et al. Involvement of 8-hydroxy-2′-deoxyguanosine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res 1997;57:1281-1287.
30. Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, Oyama K, et al. Effects of Sho-Saito-to on hepatocarcinogenesis and 8-hydroxy-2′- deoxyguanosine formation. HEPATOLOGY 2002;35:1125-1133.
31. Chittusri S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
32. Muerhoff AS, Griffin KJ, Johnson EF. The peroxisome proliferator- activated receptor mediates the induction of CYP4a6, a cytochrome P450 fatty acid ω-hydroxylase, by clofibric acid. J Biol Chem 1992; 267:19051-19053.
33. Yeldandi AV, Rao MS, Reddy LK. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat Res 2000;448:159-177.
34. He T-C, Chan TA, Vegelstein B, Kinzler KW. PPARβ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-345.
35. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A 2001;98:2598-2603.
36. Fan C-Y, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. J Biol Chem 1998;273:15639-15645.
37. Ames BN, Gold LS, Willet WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A 1995;92:5258-5265.
38. Moriya K, Todoroki T, Tsutsumi T, Fujie H, Shintani Y, Miyoshi H, et al. Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. Biochem Biophys Res Commun 2001;281:1207-1212.
39. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-1067.
40. Perlemuter G, Sabile A, Letterron P, Vona G, Topilco A, Chretien Y, et al. Hepatitis C core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185-194.
41. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002;122:352-365.